{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-069176","form_type":"8-K","ticker":"KPTI","cik":"0001503802","company_name":"Karyopharm Therapeutics Inc.","filed_at":"2025-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.514268+00:00","generated_at":"2026-05-21T23:32:09.753911+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Karyopharm Reports Q1 2025 Revenue of $30.0M, Net Loss of $23.5M; Phase 3 SENTRY Trial Passes Futility Analysis","bullets":["Total revenue $30.0M; U.S. XPOVIO net product revenue $21.1M, impacted by $5.0M increase in product return reserve for expired 80 mg and 100 mg units.","Phase 3 SENTRY trial (selinexor + ruxolitinib) passed futility analysis, is ~80% enrolled; target enrollment expected June/July 2025.","Phase 2 XPORT-MF-035 data: selinexor monotherapy achieved SVR25 in 67% of evaluable patients vs 38% with physician's choice.","Reaffirms full-year 2025 guidance: total revenue $140M–$155M, U.S. XPOVIO net product revenue $115M–$130M.","Cash, cash equivalents and investments $70.3M as of March 31, 2025; exploring alternatives to extend cash runway."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-069176","json":"https://secwatch.observer/filing/0000950170-25-069176.json","markdown":"https://secwatch.observer/filing/0000950170-25-069176.md","text":"https://secwatch.observer/filing/0000950170-25-069176.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1503802/000095017025069176/0000950170-25-069176-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1503802/000095017025069176/kpti-20250512.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-21T23:32:09.753911+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}